Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Phil on +44 1494 818 008 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Phil Hardy
Senior Account Manager
+44 1494 818 008

Many thanks again for all your advice and support which has enabled me to secure my new role. Your hard work and input has been very much appreciated.
Claire , 2013

Bayer HealthCare forms new radiology and interventional unit

5 March 2012 00:00 in Medical Company Restructures

Bayer HealthCare has announced the formation of a new radiology and interventional business unit as it looks to streamline and realign its portfolio for growth.

The division is being created through the integration of its subsidiary Medrad and Bayer HealthCare Pharmaceuticals' contrast media business, with the Medrad name set to become a Bayer product brand.

Following the reorganisation, the newly launched unit will be responsible for product lines including Gadovist, Ultravist, AngioJet Ultra and the Mark 7 Arterion Injection System, with its headquarters based in New York.

It will operate within Bayer HealthCare's medical care division, led by executive committee member Alan Main.

Dr Joerg Reinhardt, chairman of the board of management at Bayer HealthCare, said: "Working over several decades, the groups that now form Bayer HealthCare Radiology and Interventional have achieved significant success ... Our commitment continues with the integration of these business groups to increase focus on shared customers."

Last month, Bayer announced record-breaking annual sales of 36.53 billion euros (30.44 billion pounds), representing a 4.1 percent year-on-year increase.ADNFCR-8000103-ID-801309842-ADNFCR

Other news stories from 05/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd